More biosimilars are marketed in Germany and Switzerland than in the USA
FRIDAY, December 2, 2022 (HealthDay News) — More biosimilars have been marketed in Germany and Switzerland than in the United States, according to a study published online December 2, but uptake has increased over time in all countries JAMA network open.
In a cohort study, David L. Carl from the University of Zurich and colleagues examined the uptake and prices of biosimilars in the United States in comparison to Germany and Switzerland. For 2011 to 2020, prices and sales data were extracted from public and commercial databases.
The study cohort included 15 biosimilars and six biologics for the United States; 52 and 15 for Germany; and 28 and 13 for Switzerland. The researchers found that the uptake of biosimilars increased over time in all countries. On average, the highest biosimilar market share was recorded at launch in Germany; However, it rose fastest in the United States. The median monthly treatment costs of biosimilars in the US were 1.94 and 2.74 higher than the corresponding costs in Germany and Switzerland.
“Policies for drug price negotiations in the United States against anti-competitive practices of exclusivity agreements could allow biosimilars to reach the market sooner and at lower costs, which could lead to lower health care costs and better access for patients,” the authors write. “Awareness of biosimilars should be promoted in order to increase the acceptance of biosimilars in all three countries.”
Copyright © 2022 health day. All rights reserved.